Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Pevonedistat · TAK-924, MLN-4924

Small molecule · Inhibitor of Nedd8 activating enzyme (NAE) · developed by TAKEDA PHARMACEUTICAL CO

Phase 2/3 Most advanced trial

TAK Developer

2 Registered trials

What is Pevonedistat?

Pevonedistat is a small molecule inhibitor of Nedd8 activating enzyme (NAE). It binds to and inhibits NAE, blocking the neddylation pathway that regulates cellular protein modification and tumor cell proliferation. It is studied in acute myeloid leukemia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: TAK-924, MLN-4924, MLN-4924003
Drug type: Small molecule
Targets: Nedd8 activating enzyme (NAE)
Mechanism: Inhibitor of Nedd8 activating enzyme (NAE)
Pathways: neddylation, ubiquitin-like protein conjugation
Therapy area: Oncology
Developer: TAKEDA PHARMACEUTICAL CO (TAK)
Also in trials of: SNDX
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2/3
UNII: S3AZD8D215

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT03013998	Phase 2/3	Previously Untreated Relapsed Refractory Acute Myeloid Leukemia	Recruiting	SNDX
NCT04266795	Phase 2	Acute Myeloid Leukemia (AML)	Completed	TAK

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Acute Myeloid Leukemia (AML)

More from TAKEDA PHARMACEUTICAL CO

Maribavir FDA approved Susoctocog Alfa FDA approved Vedolizumab FDA approved Vonicog Alfa FDA approved Elritercept Phase 3 GDX012 Phase 1/2 IGI Phase 3 Mezagitamab Phase 3 MNI-792 Phase 1 Soticlestat Phase 3 TAK-186 Phase 1/2 TAK-188 Phase 1/2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the TAK page.

Follow TAK, the company behind Pevonedistat

See TAK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

TAK catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z